Overview

A Study of ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

Status:
Not yet recruiting

Trial end date:
2025-06-23

Target enrollment:

Participant gender:

Summary

This Phase 2 clinical study will evaluate ALX148 in combination with cetuximab and pembrolizumab for refractory microsatellite stable metastatic colorectal cancer

Phase:

Phase 2

Details

Lead Sponsor:

Criterium, Inc.

Collaborators:

ALX Oncology Inc.
Eli Lilly and Company
Merck Sharp & Dohme Corp.

Treatments:

Cetuximab
Pembrolizumab